Uwe Schlegel

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack et al. · The Lancet · 2019 · 576 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Roger Stupp, Monika E. Hegi, Bart Neyns et al. · Journal of Clinical Oncology · 2010 · 443 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Hendrik Pels, Ingo G.H. Schmidt‐Wolf, Axel Glasmacher et al. · Journal of Clinical Oncology · 2003 · 423 citations

Medicine, Oncology, Pharmacotherapy +13

Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients

Dieter Lütjohann, Andreas Papassotiropoulos, Ingemar Björkhem et al. · Journal of Lipid Research · 2000 · 379 citations · Full text

Life Sciences, Biochemistry, Neurology +17

<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Michael Weller, Ghazaleh Tabatabai, Bärbel Kästner et al. · Clinical Cancer Research · 2015 · 318 citations · Full text

Medicine, Oncology, Pharmacology +17